Scholarlink

<p>Glioblastoma continues to have a poor prognosis, although recent advancements in multimodal treatments have gradually improved outcomes. However, treatment options have become increasingly complex and highly specialized. In rural areas, patients often travel long distances for treatments such as bevacizumab (BEV) administration, which may hinder treatment adherence and potentially lead to poorer outcomes. This study analyzed the impact of commuting distance on survival using clinical data from the Kyushu Neuro-Oncology Study Group. We measured the commuting distances of 564 patients with glioblastoma who were initially treated at 11 participating institutions between 2010 and 2023. Patients were categorized into nearby and remote groups using a threshold of 20&#xa0;km, and their overall survival (OS) was analyzed using the Kaplan–Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards model, incorporating additional potential prognostic factors. In the overall cohort, there was no significant difference in OS between the nearby and remote groups (median OS: 19.2 vs. 18.3&#xa0;months). However, among the 452 patients who underwent second-line treatment for recurrence, OS was significantly longer in the nearby group (median OS: 18.7 vs. 16.8&#xa0;months). Univariate analysis revealed that commuting distance (P = 0.037), age, extent of resection, and performance status (PS) were all significant prognostic factors. Multivariate analysis demonstrated that commuting distance was an independent prognostic factor (P = 0.009). These results were validated through propensity score matching, which analyzed 148 patients in each group (median OS: 19.3 vs. 16.4&#xa0;months). Our findings suggest that commuting distance is associated with prognosis in glioblastoma patients who require second-line treatment. To address this issue, it is necessary to establish an environment that enables the smooth and continuous delivery of multimodal treatment, particularly in rural areas.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rural medical disparities in multimodal glioblastoma treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月25日

查看全文
  • Yasutomo Momii,
  • Nobuhiro Hata,
  • Hirotaka Fudaba,
  • Hajime Yonezawa,
  • Naoki Shinojima,
  • Tetsuya Negoto,
  • Kenta Ujifuku,
  • Hideki Nagamine,
  • Daisuke Kuga,
  • Yukiko Nakahara,
  • Shinji Yamashita,
  • Yoshiteru Nakano,
  • Toshiyuki Enomoto,
  • Ryosuke Hanaya,
  • Akitake Mukasa,
  • Motohiro Morioka,
  • Takayuki Matsuo,
  • Tadashi Hamasaki,
  • Koji Yoshimoto,
  • Tatsuya Abe,
  • Yoshiko Okita,
  • Junkoh Yamamoto,
  • Hiroshi Abe,
  • Minoru Fujiki,
  • Nayuta Higa,
  • Kenji Fujimoto,
  • Hirotaka Inoue,
  • Kiyohiko Sakata,
  • Hidenobu Yoshitake,
  • Aya Hashimoto,
  • Takeshi Hiu,
  • Hokama Yohei,
  • Ryusuke Hatae,
  • Yutaka Fujioka,
  • Namikawa Hiroki,
  • Ito Hiroshi,
  • Kiyotaka Saito,
  • Fumitaka Matusmoto,
  • Kohei Suzuki,
  • Shohei Nagasaka

摘要

Glioblastoma continues to have a poor prognosis, although recent advancements in multimodal treatments have gradually improved outcomes. However, treatment options have become increasingly complex and highly specialized. In rural areas, patients often travel long distances for treatments such as bevacizumab (BEV) administration, which may hinder treatment adherence and potentially lead to poorer outcomes. This study analyzed the impact of commuting distance on survival using clinical data from the Kyushu Neuro-Oncology Study Group. We measured the commuting distances of 564 patients with glioblastoma who were initially treated at 11 participating institutions between 2010 and 2023. Patients were categorized into nearby and remote groups using a threshold of 20 km, and their overall survival (OS) was analyzed using the Kaplan–Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards model, incorporating additional potential prognostic factors. In the overall cohort, there was no significant difference in OS between the nearby and remote groups (median OS: 19.2 vs. 18.3 months). However, among the 452 patients who underwent second-line treatment for recurrence, OS was significantly longer in the nearby group (median OS: 18.7 vs. 16.8 months). Univariate analysis revealed that commuting distance (P = 0.037), age, extent of resection, and performance status (PS) were all significant prognostic factors. Multivariate analysis demonstrated that commuting distance was an independent prognostic factor (P = 0.009). These results were validated through propensity score matching, which analyzed 148 patients in each group (median OS: 19.3 vs. 16.4 months). Our findings suggest that commuting distance is associated with prognosis in glioblastoma patients who require second-line treatment. To address this issue, it is necessary to establish an environment that enables the smooth and continuous delivery of multimodal treatment, particularly in rural areas.